Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose ambroxol plus enzyme replacement therapy in Gaucher disease (Phase I/II, open-label)
KCT0009450Phase 2Active, not recruiting
- Sponsor
- ISU Abxis Co., Ltd.
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ambroxol in Gaucher disease (GD), sponsored by ISU Abxis Co., Ltd. Started Nov 2022; status: active, not recruiting.
02
Drugs
ambroxol
03
Conditions
Gaucher disease (GD)
Beyond the preview
Go deeper on KCT0009450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009450.